NASDAQ · IMMX
Immix Biopharma, Inc.
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
Loading market information…
NASDAQ · SRZN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Surrozen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Surrozen, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$1.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Surrozen, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 9, 2025 |
| -$7.43-581.65% vs estimate |
| $991.50K |
| Q4 2024 | Mar 31, 2025 | -$9.10-258.27% vs estimate | $655.00K |
|---|
| Q3 2024 | Nov 6, 2024 | -$0.44+84.12% vs estimate | $10.00M |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $54.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.98-$0.15 (-1.78%)
Immix Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.15% below the high.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
$19.00+$0.69 (+3.77%)
Greenwich LifeSciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.28% below the high.
$1.94-$0.05 (-2.51%)
Seer, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.49% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$6.83+$0.04 (+0.52%)
Instil Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
$6.05-$0.19 (-3.04%)
Tevogen Bio Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.38% below the high.
